150 related articles for article (PubMed ID: 12749895)
1. Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
Wallace OB; Lauwers KS; Jones SA; Dodge JA
Bioorg Med Chem Lett; 2003 Jun; 13(11):1907-10. PubMed ID: 12749895
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.
Shen J; Jiang J; Kuang G; Tan C; Liu G; Huang J; Tang Y
Eur J Med Chem; 2012 Aug; 54():188-96. PubMed ID: 22647217
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
4. Structure-based approach for the discovery of novel selective estrogen receptor modulators.
Rosano C; Stec-Martyna E; Lappano R; Maggiolini M
Curr Med Chem; 2011; 18(8):1188-94. PubMed ID: 21291367
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
Chen HY; Kim S; Wu JY; Birzin ET; Chan W; Yang YT; Dahllund J; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 May; 14(10):2551-4. PubMed ID: 15109649
[TBL] [Abstract][Full Text] [Related]
6. A new series of estrogen receptor modulators: effect of alkyl substituents on receptor-binding affinity.
Kamada A; Sasaki A; Kitazawa N; Okabe T; Nara K; Hamaoka S; Araki S; Hagiwara H
Chem Pharm Bull (Tokyo); 2004 Jan; 52(1):79-88. PubMed ID: 14709872
[TBL] [Abstract][Full Text] [Related]
7. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
8. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z
J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.
Chesworth R; Zawistoski MP; Lefker BA; Cameron KO; Day RF; Mangano FM; Rosati RL; Colella S; Petersen DN; Brault A; Lu B; Pan LC; Perry P; Ng O; Castleberry TA; Owen TA; Brown TA; Thompson DD; DaSilva-Jardine P
Bioorg Med Chem Lett; 2004 Jun; 14(11):2729-33. PubMed ID: 15125923
[TBL] [Abstract][Full Text] [Related]
10. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.
Zheng Y; Zhu M; Srinivasan S; Nwachukwu JC; Cavett V; Min J; Carlson KE; Wang P; Dong C; Katzenellenbogen JA; Nettles KW; Zhou HB
ChemMedChem; 2012 Jun; 7(6):1094-100. PubMed ID: 22517684
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
Blizzard TA; DiNinno F; Chen HY; Kim S; Wu JY; Chan W; Birzin ET; Yang YT; Pai LY; Hayes EC; DaSilva CA; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2005 Sep; 15(17):3912-6. PubMed ID: 15993065
[TBL] [Abstract][Full Text] [Related]
12. Benzothiophene and naphthalene derived constrained SERMs.
Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
[TBL] [Abstract][Full Text] [Related]
14. Development of Photoswitchable Estrogen Receptor Ligands.
Tsuchiya K; Umeno T; Tsuji G; Yokoo H; Tanaka M; Fukuhara K; Demizu Y; Misawa T
Chem Pharm Bull (Tokyo); 2020; 68(4):398-402. PubMed ID: 32238658
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.
Zheng Y; Wang C; Li C; Qiao J; Zhang F; Huang M; Ren W; Dong C; Huang J; Zhou HB
Org Biomol Chem; 2012 Dec; 10(48):9689-99. PubMed ID: 23149805
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
Hoekstra WJ; Patel HS; Liang X; Blanc JB; Heyer DO; Willson TM; Iannone MA; Kadwell SH; Miller LA; Pearce KH; Simmons CA; Shearin J
J Med Chem; 2005 Mar; 48(6):2243-7. PubMed ID: 15771467
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.
Yadav Y; Maclean ED; Bhattacharyya A; Parmar VS; Balzarini J; Barden CJ; Too CK; Jha A
Eur J Med Chem; 2011 Sep; 46(9):3858-66. PubMed ID: 21680064
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor ligands. Part 6: Synthesis and binding affinity of dihydrobenzodithiins.
Tan Q; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 Jul; 14(14):3753-5. PubMed ID: 15203156
[TBL] [Abstract][Full Text] [Related]
19. Identification of 10-dehydrooxyglycyuralin E as a selective human estrogen receptor alpha partial agonist.
Saito N; Kawase K; Yamashita N; Tang Y; Wang Y; Wang J; Liu Y; Li N; Li W; Cheng MS; Koike K; Kanno Y; Nemoto K
Bioorg Chem; 2019 Jul; 88():102977. PubMed ID: 31100617
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
